Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection

Liver International

Volumn 32, Issue 5, 2012, Pages 803-808

  Danilovic, Debora L S ^a   Mendes Correa, Maria C ^a   Lima, Érika U ^a   Zambrini, Heverton ^a   K Barros, Raffaelle ^b   Marui, Suemi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

Author keywords

CTLA 4; Hepatitis C; Hepatitis C virus genotype; Necroinflammatory activity score

Indexed keywords

AMINOTRANSFERASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA FRAGMENT;

3' UNTRANSLATED REGION; ADULT; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENE FREQUENCY; GENETIC CORRELATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

CTLA-4 ANTIGEN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859439963     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02694.x     Document Type: Article

References (32)

1. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-8.
2. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
3. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002; 3: 233-4.
4. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002; 277: 46478-86.
5. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
6. Wang XB, Kakoulidou M, Giscombe R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002; 130: 224-32.
7. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24: 694-717.
8. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170-84.
9. Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264-71.
10. Schott E, Witt H, Hinrichsen H, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol 2007; 46: 372-80.
11. Nischalke HD, Vogel M, Mauss S, et al. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection. Aids 2010; 24: 2001-7.
12. Schott E, Witt H, Pascu M, et al. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007; 19: 947-51.
13. Mendes-Correa MC, Widman A, Brussi ML, et al. Clinical and histological characteristics of HIV and hepatitis C virus-co-infected patients in Brazil: a case series study. Rev Inst Med Trop Sao Paulo 2008; 50: 213-7.
14. Gayotto LCC, Comitê SBP/SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. GED 2000; 19: 137-140.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
16. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996; 225: 817-8.
17. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001; 86: 1687-93.
18. Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165: 6606-11.
19. Ban Y, Concepcion ES, Villanueva R, et al. Analysis of immune regulatory genes in familial and sporadic Graves' disease. J Clin Endocrinol Metab 2004; 89: 4562-8.
20. Ahmed S, Ihara K, Kanemitsu S, et al. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford) 2001; 40: 662-7.
21. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.
22. Kuzushita N, Hayashi N, Moribe T, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-4.
23. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
24. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-90.
25. Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006; 80: 9144-50.
26. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
28. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol 1999; 11: 294-300.
29. Itose I, Kanto T, Kakita N, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat 2009; 16: 844-52.
30. Zein NN, Germer JJ, El-Zayadi AR, Vidigal PG. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg 2004; 70: 434-7.
31. Kamal SM. Determinants of treatment outcomes for Hepatitis C infection and the path to personalized medicine. Curr Pharmacogenomics Person Med 2011; 9: 123-136.
32. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 2007; 8: 1299-306.